BINDING OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-I (HIV-1) GP120 TO GALACTOSYLCERAMIDE (GALCER) - RELATIONSHIP TO THE V3 LOOP

被引:101
|
作者
COOK, DG
FANTINI, J
SPITALNIK, SL
GONZALEZSCARANO, F
机构
[1] UNIV PENN, MED CTR, DEPT NEUROL, PHILADELPHIA, PA 19104 USA
[2] UNIV PENN, MED CTR, DEPT MICROBIOL, PHILADELPHIA, PA 19104 USA
[3] FAC MED MARSEILLE, CNRS, URA 1455, F-13385 MARSEILLE, FRANCE
[4] UNIV PENN, MED CTR, DEPT LAB MED & PATHOL, PHILADELPHIA, PA 19104 USA
关键词
D O I
10.1006/viro.1994.1287
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The primary receptor for the human immunodeficiency virus (HIV) is the CD4 molecule. However, a large body of evidence has demonstrated that some cells that do not express the CD4 receptor can be infected by HIV-1 and HIV-2, indicating that an alternative mechanism of infection must exist for some cell types. Recently it was reported that antibodies against the glycosphingolipid, galactosylceramide (Gal beta 1-1'Cer; GalCer), blocked infection of several CD4 negative cell lines derived from the brain and colon. The hypothesis that GalCer might be involved in the process of HIV entry into these cells was further supported by the finding that recombinant gp120 bound GalCer with high affinity in a high performance thin layer chromatography (HPTLC) binding assay. We have examined the interactions between GalCer and gp120, and found that the oligosaccharides that constitute a large proportion of the molecular mass of this glycoprotein are not involved in binding to this glycolipid. Furthermore, using a panel of monoclonal and monospecific antibodies we have determined that gp120 binds GalCer, and the related molecule 3' sulfo galactosylceramide (sulfatide), at a site that is conformationally close to the its principal neutralizing domain (V3 loop) or at the V3 loop itself. (C) 1994 Academic Press, Inc.
引用
收藏
页码:206 / 214
页数:9
相关论文
共 50 条
  • [21] INHIBITION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION AND SYNCYTIUM FORMATION IN HUMAN-CELLS BY V3 LOOP SYNTHETIC PEPTIDES FROM GP120
    NEHETE, PN
    ARLINGHAUS, RB
    SASTRY, KJ
    JOURNAL OF VIROLOGY, 1993, 67 (11) : 6841 - 6846
  • [22] Structural descriptors of gp120 V3 loop for the prediction of HIV-1 coreceptor usage
    Sander, Oliver
    Sing, Tobias
    Sommer, Ingolf
    Low, Andrew J.
    Cheung, Peter K.
    Harrigan, P. Richard
    Lengauer, Thomas
    Domingues, Francisco S.
    PLOS COMPUTATIONAL BIOLOGY, 2007, 3 (03) : 555 - 564
  • [23] STEREOCHEMICAL ANALYSIS OF THE ANTIGENIC TIP OF THE V3 LOOP PEPTIDE OF HIV-1 GP120
    GUNASEKARAN, K
    RAMAKRISHNAN, C
    BALARAM, P
    INTERNATIONAL JOURNAL OF PEPTIDE AND PROTEIN RESEARCH, 1995, 46 (05): : 359 - 365
  • [24] HIV-1 gp120 V3 loop for structure-based drug design
    Sirois, S
    Sing, T
    Chou, KC
    CURRENT PROTEIN & PEPTIDE SCIENCE, 2005, 6 (05) : 413 - 422
  • [25] Molecular Recognition of CCR5 by an HIV-1 gp120 V3 Loop
    Tamamis, Phanourios
    Floudas, Christodoulos A.
    PLOS ONE, 2014, 9 (04):
  • [26] Pseudoprolines: Targeting a cis Conformation in a Mimetic of the gp120 V3 Loop of HIV-1
    Wittelsberger, Angela
    Keller, Michael
    Scarpellino, Leo
    Patiny, Luc
    Acha-Orbea, Hans
    Mutter, Manfred
    2000, Wiley-VCH Verlag (39):
  • [27] HIV-1 GP120 V3 conformational and informational entropies
    Weltman, JK
    Skowron, G
    Loriot, GB
    JOURNAL OF MOLECULAR MODELING, 2006, 12 (03) : 362 - 365
  • [28] Dual specificity of a human neutralizing monoclonal antibody, specific for the V3 loop of GP120 (HIV-1)
    Laisney, IL
    Strosberg, AD
    IMMUNOLOGY LETTERS, 1999, 67 (03) : 185 - 192
  • [29] Broadly reactive antibodies against a gp120 V3 loop multi-epitope polypeptide neutralize different isolates of human immunodeficiency virus type 1 (HIV-1)
    Montero, M
    Menendez, A
    Dominguez, MD
    Navea, L
    Vilarubia, OL
    Quintana, D
    Izquierdo, M
    Jimenez, V
    Reyes, O
    Lobaina, L
    Noa, E
    Duarte, CA
    VACCINE, 1997, 15 (11) : 1200 - 1208
  • [30] Apoptosis induction by human immunodeficiency virus type 1 (HIV-1) gp120 peptides
    Pugliese, O
    Boirivant, M
    Viora, M
    VIRAL IMMUNOLOGY, 1997, 10 (02) : 95 - 102